Monday, August 4, 2025

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Related stories

SAFE Raises $70M to Build CyberAGI, Launches CTEM AI

SAFE, a recognized leader in Cyber Risk Quantification (CRQ)...

Informatica Enhances AI in New Data Management Platform

Informatica has rolled out significant updates to its Intelligent...

Globant Enterprise AI Enables A2A and Powers Business AI

Enhanced by these protocols, Globant Enterprise AI positions itself...

Knit Raises $16.1M to Redefine Enterprise Insights with AI

With $30M+ in total funding, Knit delivers human and...
spot_imgspot_img

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.

“Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety,” said Joseph Schmidt, chief operating officer, Medidata. “By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience and expertise in these two important therapeutic areas. These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments.”

Also Read: Tevogen AI Partners with Microsoft to Speed Drug Development

Medidata, with more than 25 years of oncology and vaccine experience and the largest global trial datasets, has conducted approximately 9,000 oncology studies and 750 trials in vaccines. In 2023, it was recorded that 93% of oncology drug approvals went through Medidata. The company was also on the frontlines of COVID-19, supporting hundreds of trials, including the development of one of the most effective mRNA vaccines used to fight the virus.

SOURCE: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img